The firm exhibits a persistent negative free cash flow trajectory, with 2025Q4 free cash flow at -$10.6K, reflecting an asset-light model focused exclusively on clinical trial execution.
| Cash from Operations | -36.99M | -29.23M | -29.84M | -11.46M | -7.47M | -4.44M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -26.52% | 2.02% | -160.4% | -53.3% | -68.26% | - |
| Net Income | -77.61M | -36.14M | -31.63M | -12.65M | -9.67M | -5.75M |
| Depreciation & Amortization | 464K | 449K | 399K | 198K | 30K | 17K |
| Stock-Based Compensation | 38.92M | 8.99M | 3.82M | 1.48M | 1.53M | 1.36M |
| Deferred Taxes | 0 | 0 | -4.69M | -1.91M | 0 | -1.39M |
| Other Non-Cash Items | -1.31M | -3.66M | 4.69M | 1.91M | -8K | 1.39M |
| Working Capital Changes | 2.55M | 1.13M | -2.43M | -491K | 640K | -69K |
| Change in Receivables | -66K | 74K | -72K | -32K | 0 | 4K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -305.11M | -110.57M | -63K | -394K | -56K | -20K |
| Capital Expenditures | -178K | -116K | -63K | -394K | -74K | -20K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 18K | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -35K | 0 | 0 | 0 | 0 |
| Cash from Financing | 663.23M | 83.59M | 75.96M | 36.96M | -583K | 28.06M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -2.32M |
| Equity Issued (Net) | 292.86M | 42.24M | 77.19M | 37.99M | -583K | 30.29M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 370.37M | 41.36M | -1.23M | -1.03M | 0 | 86K |
| Net Change in Cash | 321.25M | -56.48M | 46.07M | 24.75M | -8.27M | 23.6M |
| Free Cash Flow | -37.17M | -29.39M | -29.9M | -11.85M | -7.55M | -4.46M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -26.48% | 1.72% | -152.28% | -57.02% | -69.16% | - |
| FCF per Share | -1.11 | -0.96 | -1.12 | -0.59 | -0.31 | -0.48 |
| FCF Conversion (FCF/Net Income) | 0.48x | 0.81x | 0.94x | 0.91x | 0.77x | 0.77x |
| Interest Paid | 1K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 6K | 9K | 0 | 0 | 0 |
Binary clinical trial outcomes
As reported in recent financial statements, Belite Bio's operating cash flow of -$10.4K in 2025Q4 stands in stark contrast to a net loss of $25.3 million, highlighting a significant disconnect between accounting losses and actual cash usage as the firm remains in a pre-revenue clinical development phase.
The minimal operating cash outflow relative to the substantial net loss suggests that a large portion of the company's reported expenses are non-cash in nature or accrued liabilities that have not yet impacted the cash balance. Investors should monitor this divergence closely, as it may indicate that the true cash burn rate is currently masked by the timing of clinical trial payments and accounting adjustments.
Based on the company's reported figures, the free cash flow trajectory remains firmly negative at -$10.6K in 2025Q4, confirming that the business continues to consume capital to fund its R&D initiatives without generating any offsetting cash inflows from commercial operations or product sales.
The absence of positive free cash flow is expected for a clinical-stage entity, yet the trend warrants investigation into how long the current cash position can sustain these outflows. The lack of revenue generation means that the company is entirely dependent on its existing capital reserves to reach critical clinical milestones.
According to recent SEC filings, Belite Bio reported a nominal capital expenditure of $178 in 2025Q4, reflecting a business model that is currently asset-light and focused primarily on outsourced clinical research rather than heavy investment in physical manufacturing or proprietary infrastructure at this stage of development.
The negligible level of capital spending suggests that the company is avoiding the burden of fixed asset ownership, which is a prudent strategy for a firm whose primary value is tied to intellectual property. However, this may change rapidly if the company decides to internalize manufacturing processes following potential regulatory approval.
As indicated in financial statements, the emergence of $11.7K in stock-based compensation during 2025Q4 serves as a non-cash adjustment that effectively reduces the reported net loss, potentially obscuring the underlying cash-based operational costs required to retain talent during the critical Phase 3 trial period.
While stock-based compensation is a standard tool for preserving cash in biotech, it represents a future dilution risk that investors must weigh against the company's current cash runway. The reliance on equity-based incentives suggests that management is attempting to align employee interests with long-term clinical success while minimizing immediate cash outflows.
Quick answers to the most common questions about buying BLTE stock.
Belite Bio, Inc (BLTE) generated $-37.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Belite Bio, Inc (BLTE) reported negative free cash flow of $37.2M in 2025, indicating capital requirements exceeded cash from operations.
Belite Bio, Inc (BLTE) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.